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RESEARCH ARTICLE Open Access
Trastuzumab-DM1 causes tumour growth
inhibition by mitotic catastrophe in trastuzumab-
resistant breast cancer cells in vivo
Mark Barok1*, Minna Tanner1,2, Katri Köninki1 and Jorma Isola1*
Abstract
Introduction: Trastuzumab is widely used for the treatment of HER2-positive breast cancer. Despite encouraging
clinical results, a significant fraction of patients are, or become, refractory to the drug. To overcome this,
trastuzumab-DM1 (T-DM1), a newer, more potent drug has been introduced. We tested the efficacy and
mechanisms of action of T-DM1 in nine HER2-positive breast cancer cell lines in vitro and in vivo. The nine cell lines
studied included UACC-893, MDA-453 and JIMT-1, which are resistant to both trastuzumab and lapatinib.
Methods: AlamarBlue cell-proliferation assay was used to determine the growth response of breast cancer cell
lines to trastuzumab and T-DM1 in vitro. Trastuzumab- and T-DM1-mediated antibody-dependent cellular
cytotoxicity (ADCC) was analysed by measuring the lactate dehydrogenase released from the cancer cells as a
result of ADCC activity of peripheral blood mononuclear cells. Severe Combined Immunodeficient (SCID) mice
were inoculated with trastuzumab-resistant JIMT-1 cells to investigate the tumour inhibitory effect of T-DM1 in vivo.
The xenograft samples were investigated using histology and immunohistochemistry.
Results: T-DM1 was strongly growth inhibitory on all investigated HER2-positive breast cancer cell lines in vitro. T-
DM1 also evoked antibody-dependent cellular cytotoxicity (ADCC) similar to that of trastuzumab. Outgrowth of
JIMT-1 xenograft tumours in SCID mice was significantly inhibited by T-DM1. Histologically, the cellular response to
T-DM1 consisted of apoptosis and mitotic catastrophe, the latter evidenced by an increased number of cells with
aberrant mitotic figures and giant multinucleated cells.
Conclusions: Our results suggest mitotic catastrophe as a previously undescribed mechanism of action of T-DM1.
T-DM1 was found effective even on breast cancer cell lines with moderate HER2 expression levels and cross-
resistance to trastuzumab and lapatinib (MDA-453 and JIMT-1).
Introduction
HER2 (ErbB2) is a member of the epidermal growth fac-
tor receptor (EGFR) family of receptor tyrosine kinases.
Its overexpression occurs in 15 to 20% of primary
human breast cancers and is associated with aggressive
growth and poor clinical outcomes [1,2]. A break-
through in medical oncology was the finding that trastu-
zumab, a recombinant humanized monoclonal antibody
against the extracellular domain of HER2, showed a sig-
nificant anti-tumour effect in a phase III clinical trial
[3]. Trastuzumab is currently used for treatment of both
metastatic and early-stage breast cancer world-wide
[3,4].
Although the mechanisms underlying the action of
trastuzumab are still not fully determined, its clinical
benefit is attributed to internalization and down-regula-
tion of cell surface HER2 [5], preventing the activation
of AKT by reducing signaling in the PI3K-PTEN path-
way [6], cell cycle arrest in G1 [7], HLA-I-restricted anti-
gen presentation of HER2 [8], inhibition of angiogenesis
[9] and evoking antibody-dependent cellular cytotoxicity
(ADCC) [10,11]. In spite of these multiple actions, a sig-
nificant number of breast cancer patients are primarily
resistant to trastuzumab, and a majority of those initially
responding become resistant during prolonged treat-
ment [12]. Primary or secondary resistance to
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trastuzumab is attributed to autocrine production of
EGF-related ligands [13], activation of the insulin-like
growth factor-I (IGF-I) receptor pathway [14], defects in
the PI3K-PTEN-AKT pathway [6,15], masking of the
trastuzumab epitope by MUC4 [16] or hyaluronan [17],
expression of p95HER2, a constitutively active truncated
form of HER2 [18], or impaired ADCC reaction [19].
Since development of trastuzumab, several other drugs
targeting the HER receptor family, have been developed
[20,21]. Of those, a small molecule kinase inhibitor lapa-
tinib has proven effective in clinical trials [22,23]. Unfor-
tunately, similar to trastuzumab, a majority of patients
responding to lapatinib become resistant and most of
trastuzumab-pretreated patients fail to respond to lapati-
nib [24]. Therefore, it is clear that more effective HER2
targeting drugs are needed.
A new strategy of anti-HER2 targeted therapy has
been achieved using antibody-drug conjugate (ADC)
technology. The monoclonal antibody trastuzumab has
been conjugated with cytotoxic molecule DM1 (deriva-
tive of maytansine 1). The resulting conjugate, named
trastuzumab-DM1 (T-DM1) is designed to deliver DM1
into the HER2 overexpressing cells via receptor-
mediated endocytosis [25]. Active DM1 is released fol-
lowing internalization of the conjugate and lysosomal
degradation [26]. Intracellular DM1 is a potent inhibitor
of microtubule assembly thereby causing cell death
[27-29]. T-DM1 is effective both in vitro and in vivo
models of trastuzumab-resistant breast cancer [25]. Very
recently, T-DM1 showed remarkable activity in phase I
and II studies in which it was given to patients with
trastuzumab-resistant HER2-positive breast cancer
[30-32].
T-DM1 has been shown to induce apoptotic cell death
[25]. Other microtubule inhibitors (such as taxanes)
might also lead to mitotic catastrophe (MC), which can
be observed histologically [33,34]. Using a trastuzumab
resistant xenograft tumour model, we showed that T-
DM1 can induce both apoptosis and mitotic cata-
strophe. The latter mechanism is described for T-DM1
for the first time.
Materials and methods
Cells
The human breast cancer cell line EFM-192A was
obtained from the German Resource Center for Biologi-
cal Material and the cell lines BT-474, MDA-361, MDA-
453, MCF-7, SK-BR-3, UACC-812, UACC-893 and ZR-
75-30 were obtained from the American Type Tissue
Culture Collection. The JIMT-1 cell line has been estab-
lished in the laboratory of Cancer Biology, University of
Tampere, Finland [35] (also available via German
Resource Center for Biological Material). The cell lines
were cultured according to recommended specifications.
Antibodies
Trastuzumab (Herceptin®) and rituximab (Mabthera®)
were purchased from Roche Ltd. (Basel, Switzerland).
Trastuzumab-DM1(T-DM1) was provided by Genentech
Inc. (South San Francisco, CA, USA) through a Materi-
als Transfer Agreement. Mouse M30 CytoDeath anti-
body was obtained from Roche Ltd., HercepTest
staining kit was purchased from DakoCytomation (Car-
pinteria, CA, USA), rabbit monoclonal antibody against
human HER2 (clone SP3) was obtained from NeoMar-
kers/Lab Vision (Fremont, CA, USA).
In vitro assay of drug sensitivity
The effects of trastuzumab and T-DM1 on cell growth
was examined by the AlamarBlue method (Invitrogen,
Carlsbad, CA, USA). The cells were trypsinised and pla-
ted in 96-well, flat-bottomed, tissue culture plates. The
effects of trastuzumab and T-DM1 were tested at a con-
centration of 0.001, 0.01, 0.1, 1, and 10 μg/ml. An MCF-
7 HER2 negative breast cancer cell line with low trastu-
zumab binding capacity was used as a negative control.
The number of viable cells was tested at 72 hours after
drug exposure by adding the AlamarBlue reagent. Fluor-
escence was measured with excitation at 544 nm and
emission at 590 nm using a Wallac Victor2 plate reader
(Perkin-Elmer, Turku, Finland). Fluorescence values of
samples were normalised with values of the cell culture
media without cells. The results presented as the pro-
portion of viable cells were calculated by dividing the
fluorescence values of drug treated samples by the fluor-
escence values of untreated control samples.
Measurement of antibody-dependent cellular cytotoxicity
(ADCC)
ADCC was analysed by measuring the lactate dehydro-
genase (LDH) released from the cancer cells as a result
of ADCC activity of peripheral blood mononuclear cells
(PBMC). PBMCs were separated from the heparinized
blood of a single healthy donor by Ficoll density gradi-
ent centrifugation (Histopaque-1077, Sigma-Aldrich, St.
Louis, MO. USA). Cancer cells (target; 5,000 to 10,000
per well) and PBMCs (effector) were co-incubated at
1:5, 1:10, 1:20, 1:40 and 1:80 target:effector ratios in 100
μL DMEM containing 5% FCS in a 96-well U-bottomed
plate in quadruplicate for six hours at 37°C with trastu-
zumab, T-DM1 or negative control antibody, rituximab
(20 μg/ml). ADCC was measured in a six-hour LDH
release assay (CytoTox Non-Radioactive Cytotoxicity
Assay, Promega Corporation, Madison, WI, USA). The
absorbance at 490 nm was recorded by using a micro-
plate reader (Model 680XR, Bio-Rad, Hercules, CA,
USA). The negative control sample (target spontaneous)
was prepared identically, contained trastuzumab or T-
DM1 or rituximab, but did not contain PBMCs; effector
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spontaneous sample contained no target cells. Tumour
cells killed by freezing at -80°C for one hour then warm-
ing up to 37°C served as positive control (target maxi-
mum). The percentage of cells killed was calculated
according to the following formula: (experimental -
effector spontaneous - target spontaneous)/(target maxi-
mum - target spontaneous) * 100.
The blood donor had given informed consent before
for obtaining a peripheral venous blood sample for
PBMC assays. These experiments were done according
to the rules of the Ethical Committee of University Hos-
pital of Tampere.
In vivo assay of drug sensitivity
Five- to eight-week-old female SCID mice (Harlan Neth-
erlands, Horst, Netherlands) were given a single subcu-
taneous injection of 5 × 106 JIMT-1 cells suspended in
100 μl cell culture medium (DMEM supplemented with
7.5% FBS). Rituximab (5 mg/kg) and trastuzumab (5
mg/kg) were given intraperitoneally (i.p.) once per week,
weekly T-DM1 (5 or 15 mg/kg) was given intravenously
(i.v.) as it has been shown to be an effective regimen by
Lewis Phillips et al. [25]. Lapatinib powder was formu-
lated prior to dosing every day in a vehicle of 0.5%
hydroxypropyl methyl cellulose and 0.1% Tween 80 and
administered orally as a suspension at a dose of 100
mg/kg for 34 days on a daily schedule [36]. Tumour
growth was measured with a caliper and tumour volume
was calculated using the formula Tvol = π/6 × larger dia-
meter × (smaller diameter)2. Animals were euthanized
by CO2 inhalation. The experiments were done with the
approval by the National Animal Experiment Board.
Immunohistochemistry
Samples of xenograft tumours were fixed in 4% buffered
formaldehyde for 24 h, processed into paraffin, then sec-
tioned at 5 μm. Sections were deparaffinized and stained
with hematoxylin and eosin (H&E). For immunohisto-
chemistry, tissue sections were deparaffinised followed
by antigen-retrieval in Tris-EDTA buffer (0.01 M pH
9.0) at high temperature (water bath, 30 minutes at 98°
C). After blocking for non-specific binding, primary
antibodies (see above) were applied at optimized con-
centrations and incubated (30 minutes at room tem-
perature). Standard peroxidase-polymer kit
(PowerVision+ poly-HRP IHC Detection Systems, Leica
Biosystems Newcastle Ltd., Newcastle, UK) was used for
visualisation, with diaminobenzidine as the chromogen
(Vector Laboratories Inc., Burlingame, USA). Slide scan-
ning was done using Aperio ScanScope XT at superre-
solution (40×).
Cells with normal and aberrant mitotic shape were
defined morphologically as described earlier [37], giant
multinucleated cells (GMC) were defined as cells with
more than three nuclei. Cells with normal and aberrant
mitotic shape and GMCs were counted in hematoxylin
and eosin stained histological sections. Apoptotic cells
were counted as positive cells using CytoDeath antibody
immunohistochemistry [38]. Cells with normal and
aberrant mitotic shape, GMCs and apoptotic cells were
counted on a minimum of 10 randomly selected × 40
high-power fields containing representative sections of
tumour. Data are presented as the average of positive
cells ± SD/field.
Statistical analysis
Data are expressed as the mean ± SE. The statistical sig-
nificance of the differences between means were deter-
mined using Student’s t test for two samples after
verifying that data passed the normality test and the
groups compared have equal variance. Unpaired groups
were compared with the Mann-Whitney U test. Differ-
ences were statistically significant at P < 0.05.
Results
In vitro sensitivity of HER2 positive breast cancer cells to
trastuzumab and T-DM1
We studied a panel of nine HER2 overexpressing breast
cancer cell lines, which have been previously determined
as sensitive to both trastuzumab and lapatinib (ZR-75-
30, BT-474, EFM-192A, SKBR-3 UACC-812), sensitive
to trastuzumab and resistant to lapatinib (MDA-361), or
resistant to both trastuzumab and lapatinib (JIMT-1,
UACC-893, MDA-453) [39].
After 72 h incubation, T-DM1 significantly inhibited
the growth of all HER2 positive cell lines compared to
trastuzumab (P < 0.05). T-DM1 produced a more pro-
nounced effect on trastuzumab- and lapatinib-sensitive
cell lines (13 to 43% of surviving cells), but inhibitory
effect was seen on MDA-361 cells (50 ± 8%) as well as on
cell lines which are resistant to both trastuzumab and
lapatinib (MDA-453, 23 ± 2%; UACC-893, 56 ± 4%;
JIMT-1, 76 ± 4%). Interestingly, the trastuzumab- and
lapatinib-resistant MDA-453 cell line was the second
most sensitive to T-DM1. No inhibition was seen in
HER2 negative control cell line (MCF-7) (Figure 1A.). T-
DM1 inhibited the growth of HER2 positive breast cancer
cells in a dose-dependent manner (Figure 1B.). Concen-
trations of T-DM1 higher than 1 μg/ml inhibited also the
growth of the HER2 negative control cell line (MCF-7),
suggesting a non-specific toxic effect (data not shown).
Next we correlated the effects of trastuzumab and T-
DM1 to the trastuzumab-binding capacity of each cell
line [40]. No significant correlations were found (R =
0.43, P = 0.19 and R = 0.58, P = 0.06, respectively)
(Figure 2A, B). No significant correlation was found
between the responsiveness to trastuzumab and T-DM1
(R = 0.6, P = 0.07, Figure 2C).
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Figure 1 In vitro effects of trastuzumab and T-DM1. A. Growth inhibitory effects of trastuzumab and T-DM1 on HER2 positive breast cancer
cell lines in vitro. T-DM1 (1 μg/ml, hatched column) significantly inhibited the growth of all HER2 positive breast cancer cell lines in comparison
to trastuzumab (10 μg/ml, black column) (*, P < 0.05). Neither trastuzumab nor T-DM1 had any growth inhibitory effect on MCF-7 cells with low
trastuzumab binding capacity. Note that trastuzumab was used in a 10-times higher dose than T-DM1. B. T-DM1 inhibited the growth of HER2
positive breast cancer cells in a dose-dependent manner. The effect of T-DM1 was tested at a concentration of 0.001, 0.01, 0.1 and 1 μg/ml. Its
dose-dependent growth inhibitory effect was seen on SKBR-3 (black circle), BT-474 (white circle) and MDA-453 (black triangle) HER2 positive
breast cancer cell lines. No inhibition of HER2 negative MCF-7 (white triangle) breast cancer cells was seen. C. Trastuzumab and T-DM1 evoke
similar efficient ADCC on HER2 positive breast cancer cells in vitro. Target tumour cells (SKBR-3, JIMT-1, MCF-7) were mixed with peripheral blood
mononuclear cells (PBMCs) freshly isolated from peripheral blood at effector/target ratios of 5:1, 10:1, 20:1, 40:1, and 80:1. ADCC was analyzed by
measuring the lactate dehydrogenase (LDH) released from the cancer cells as a result of ADCC activity of PBMCs in the presence of trastuzumab,
T-DM1 or control antibody (rituximab) (20 μg/ml). The percentage of killed cells was calculated as described in Materials and methods. Killing of
SKBR-3 cells was significantly higher in the presence of both trastuzumab (blue) and T-DM1 (pink) in comparison to that in the presence of
control antibody (yellow) when the effector/target cell ratio was 5 or above (blue and pink stars, P < 0.05). Similarly, significantly higher killing of
JIMT-1 cells was detected in the presence of both trastuzumab (gray) and T-DM1 (brown) compared to that in the presence of control antibody
(pale blue) when the effector/target cell ratio was 20 or above (gray and brown stars, P < 0.05). Trastuzumab and T-DM1 evoked similar tumour
cell killing on the HER2 positive breast cancer cell lines (SKBR-3 and JIMT-1). MCF-7 cells with weak trastuzumab binding capacity showed low
levels of both trastuzumab- and T-DM1-evoked ADCC-mediated killing (red and green, respectively).
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Trastuzumab- and T-DM1-mediated ADCC against HER2
positive breast cancer cells
Since it was previously shown that antibody-dependent
cellular cytotoxicity (ADCC) has a key role in the in
vivo effect of trastuzumab [10], we compared trastuzu-
mab and T-DM1 in in vitro ADCC assay. Trastuzumab
and T-DM1 evoked ADCC similarly on SKBR-3 and
JIMT-1 breast cancer cells with dose-dependent cell
death reaching approximately 70 to 85% killing using an
effector/target ratio of 80:1. Therefore, conjugation with
DM1 does seem not to alter the ability of trastuzumab
to mediate ADCC (Figure 1C.).
Effect of T-DM1 on JIMT-1 xenografts
The effects of T-DM1 were next studied in vivo using
JIMT-1 xenograft models. Tumours were formed in all
SCID mice inoculated with JIMT-1 cell suspension in
11 days (n = 18, mean tumour volume 64 ± 9 mm3).
Thereafter, weekly treatments with trastuzumab and T-
DM1 were started on Day 12 and continued until the
end of the experiment. Rituximab was used as a negative
control agent. While trastuzumab had no inhibitory
effect on tumour growth, a partial but significant
tumour growth inhibition was seen by T-DM1 from
days 32 to 44 (P < 0.05) (Figure 3.).
The effect of T-DM1 on the formation of JIMT-1
xenografts
In the next experiment, T-DM1 treatment was started at
the time of JIMT-1 cell suspension inoculation to see its
effect on tumour formation. The tumours in T-DM1 trea-
ted mice remained very small until Day 55 (16 ± 12 mm3).
Figure 2 Correlations of drug responses and trastuzumab binding capacities. A. Correlation of response to trastuzumab and trastuzumab
binding capacity. No significant correlation was found when trastuzumab binding capacities (determined by flow cytometry [40]) were plotted
against trastuzumab sensitivities of the breast cancer cell lines (R = 0.43, P = 0.19). Trastuzumab sensitivities are expressed in proportion to the
BT-474 cell line. B. Correlation of response to T-DM1 and trastuzumab binding capacity. No significant correlation was found when trastuzumab
binding capacities were plotted against T-DM1 sensitivities of the breast cancer cell lines (R = 0.58, P = 0.06). T-DM1 sensitivities are expressed in
proportion to the BT-474 cell line. C. Correlation of trastuzumab and T-DM1 responses. Effects of both drugs on breast cancer cell lines were
plotted. No significant correlation was found between the responsiveness to trastuzumab and T-DM1 (R = 0.6, P = 0.07). Drug sensitivities are
expressed in proportion to the BT-474 cell line.
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Thereafter, the tumours started to grow in four out of six
mice but remained non-palpable in two (2/6). Residual
cancer cells were found histologically in one of these two
mice, and a complete cure was suggested in the other.
Overall, the effect of T-DM1 on tumour growth was much
stronger when compared to trastuzumab or lapatinib (P <
0.05) (Figure 4.). In this setting we also tested lapatinib,
which had no inhibitory effect on tumour growth in com-
parison to the control (Figure 4.).
Effect of T-DM1 on JIMT-1 xenografts pretreated with
trastuzumab
T-DM1 was tested also on mice treated first with trastu-
zumab since tumour cell inoculation (Day 0). As also
shown before [11], trastuzumab slowed down the forma-
tion of tumours between days 6 and 34 (P < 0.05), prob-
ably via ADCC. For half of the mice trastuzumab was
discontinued and switched to T-DM1 from Day 41
onwards. In this setting, T-DM1 was unable to inhibit
tumour growth (Figure 4.).
T-DM1 evokes mitotic catastrophe
Histological sections of the xenograft tumours were pre-
pared and stained with hematoxylin and eosin. Enu-
meration of mitoses with normal morphology revealed
no differences between trastuzumab and T-DM1 treated
JIMT-1 xenografts (Figures 5A and 6A). In contrast, we
detected a significantly higher number of cells with
aberrant mitotic morphology in T-DM1-treated tumours
(P < 0.05) (Figures 5B and 6B). In line with this observa-
tion, the number of giant multinucleated cells (GMCs)
was increased in T-DM1 treated samples (P < 0.05) (Fig-
ures 5C and 6B, D). Aberrant mitosis and GMCs are
hallmarks of mitotic catastrophe. We observed a higher
number of cells with aberrant mitotic morphology and
higher number of GMCs also in the tumour samples
whose trastuzumab-treatment were changed to T-DM1
(P < 0.05) (Figure 5B, C.).
T-DM1 evokes apoptosis
Apoptotic cells were detected using CytoDeath staining,
which localizes a caspase-activated breakdown product
of cytokeratin subtype 18. In this analysis we found sig-
nificantly increased numbers of apoptotic cells in the T-
DM1 treated samples in comparison to the trastuzumab
treated ones (P < 0.05) (Figures 5D and 6E, F). We
detected higher numbers of apoptotic cells also in the
samples whose trastuzumab-treatment were changed to
T-DM1 (P < 0.05) (Figure 5D.). It is also noteworthy
that most of the cells with aberrant mitotic morphology
were CytoDeath negative (Figure 6F).
Expression of HER2 protein on trastuzumab and T-DM1
treated xenografts
Immunohistochemical staining localizing intracellular
and extracellular epitopes of the HER2 protein was per-
formed (using HercepTest and SP3 antibodies). No
major qualitative changes in the cell membrane staining
of HER2 expression were observed. Virtually all tumour
cells showed strongly positive cell membrane staining
reactions for both intracellular and extracellular epitopes
(data not shown). However, it is noteworthy that stain-
ing positive intracytoplasmic granules were seen only in
T-DM1 treated tumours. Cells undergoing mitotic cata-
strophe were strongly positive for cell membrane HER2
protein (Figure 6C, D).
Discussion
Trastuzumab-DM1 (T-DM1) is a new antibody-drug
conjugate (ADC) developed for the treatment of HER2
positive cancer. In the present study we showed that
long-term T-DM1 treatment may have two mechanisms
of action. In addition to induction of apoptotic cell death
[25], histopathological and immunohistochemical exami-
nation of the JIMT-1 xenograft tumours revealed aber-
rant mitotic figures and giant multinucleated cells
(GMC), which are hallmarks of mitotic catastrophe (MC)
[33,34]. To the best of our knowledge, this is the first
report which shows that T-DM1 evokes mitotic cata-
strophe on cancer cells in vivo. This observation is in line
with the previous report that unconjugated maytansine
caused multinucleation of leukemic cells in vitro [41].
Figure 3 Effect of T-DM1 on the growth of JIMT-1 xenografts.
SCID mice were injected s.c. with 5 × 106 JIMT-1 cells. Tumours
were formed in all mice in 11 days (n = 18, mean tumour volume
64 ± 9 mm3). Thereafter, weekly treatments (arrows) with control
antibody (rituximab, 5 mg/kg, i.p., white circle, n = 6), trastuzumab
(5 mg/kg, i.p., black triangle, n = 6) or T-DM1 (15 mg/kg, i.v., white
triangle, n = 6) were started on Day 12 and continued until the end
of the experiment. A partial but significant tumour growth
inhibition was seen by T-DM1 from days 32 to 44 (*, P < 0.05), while
trastuzumab had no inhibitory effect on tumour growth.
Barok et al. Breast Cancer Research 2011, 13:R46
http://breast-cancer-research.com/content/13/2/R46
Page 6 of 11
Figure 4 Effect of T-DM1 on the formation of JIMT-1 xenografts. SCID mice injected s.c. with 5 × 106 JIMT-1 cells were treated on a weekly
basis with control antibody (rituximab, 5 mg/kg, i.p., black circle, n = 7), trastuzumab (5 mg/kg, i.p., red triangle, n = 6), T-DM1 (5 mg/kg, i.v.,
green triangle, n = 6) or on a daily basis with lapatinib (100 mg/kg, p.o., brown circle, n = 7) starting from the day of tumour inoculation (Day 0).
Drug administration schedule is shown by arrows. Lapatinib (brown circle) had no effect on tumour growth. Trastuzumab (red triangle) reduced
the formation of tumours between days 6 and 34 compare to both control antibody and lapatinib (red stars, P < 0.05). In three out of the six
trastuzumab treated mice, trastuzumab administration was suspended and switched to T-DM1 (5 mg/kg, i.v., yellow square) from the Day 41
(marked by white arrow) whereas it was continued for another three weeks in the other three (5 mg/kg, i.p., blue square). In this setting, T-DM1
was unable to inhibit tumour growth. The tumours started to grow in four T-DM1 treated mice (green triangle) from Day 55 onward, but
remained non-palpable in two (2/6). T-DM1 administration of these two mice was suspended on Day 76 (marked by Ο) and the mice were
followed up for more four weeks (pale blue square, n = 2). In these two mice, a very small palpable tumour (approximately 4 mm3) was
detected in one mouse on Day 107 and residual cancer cells were found histologically. No tumour was detected in the other mouse and the
histological examination of the tumour inoculation site suggested a complete cure. T-DM1 treatment of the other four mice was continued until
the end of the experiment (5 mg/kg, i.v., pink square, n = 4). Overall, T-DM1 significantly inhibited the tumour formation from Day 13 to Day 34
in comparison to both control antibody and lapatinib (green stars, P < 0.05), and it had a significantly growth inhibition between days 13 and
62 compared to trastuzumab (green a, P < 0.05). Note that both trastuzumab and T-DM1 were used in a dose of 5 mg/kg.
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Our experiments showed that T-DM1 has a strong
growth inhibitory effect on trastuzumab sensitive and
resistant HER2 positive breast cancer cell lines in vitro.
T-DM1 inhibited also the growth of breast cancer cell
lines which are cross-resistant to trastuzumab and lapa-
tinib, suggesting that T-DM1 can circumvent the cross-
resistance phenomenon. We focused our studies on the
JIMT-1 breast cancer cell line, which is unique because
of having several co-existing trastuzumab resistance
mechanisms, including an activating mutation of the
PIK3CA gene, low expression of PTEN, high expression
of NRG1, and moderate expression of HER2 receptor
(despite gene amplification). These features are present
at variable levels in other breast cancer cell lines,
whereas JIMT-1 is unique in displaying all these factors
at the same time [40].
Based on our observations, apoptosis and MC occur in
the same tumour. Data from experimental docetaxel
therapy suggest that mitotic arrest and apoptosis can be
seen at high drug concentrations, whereas aberrant
mitosis and multinucleation are observed at low concen-
trations [42]. We hypothesize that T-DM1 might also
have this dual mechanism of cytotoxicity. A high con-
centration of free DM1 in the cytoplasm might cause
rapid apoptosis with no or few MC histologically detect-
able. When the treatment target (like the JIMT-1 cell
line) is not fully sensitive to T-DM1, mitotic catastrophe
develops as a more chronic and mild late effect. The
level of HER2 expression, internalization rate of HER2 -
T-DM1 complexes, rate of lysosomal degradation or
recycling, and potential efflux of free DM1 by ABC-
transporters [26] all might define the degree of effect.
Figure 5 T-DM1 induced mitotic catastrophe and apoptosis in JIMT-1 xenografts. For histology, JIMT-1 tumours were obtained from SCID
mice treated with control antibody (rituximab, black column), lapatinib (gray column), trastuzumab (white column), T-DM1 (hatched column) or
T-DM1 after trastuzumab (cross-hatched column). Histological sections were stained with hematoxylin and eosin. When enumerating the number
of mitoses with normal morphology, no differences were found between the samples (A). In contrast, a significantly higher number of cells with
aberrant mitotic morphology was detected in T-DM1 treated tumours (B) (*, P < 0.05). The number of giant multinucleated cells was also
increased in T-DM1 treated samples (C) (*, P < 0.05). Notably, higher number of cells with aberrant mitotic morphology and higher number of
giant multinucleated cells were detected in the samples whose trastuzumab treatment was changed to T-DM1 (B-C) (*, P < 0.05). CytoDeath
staining was used to detect the apoptotic cells in the histological sections. Significantly increased number of apoptotic cells was found in the T-
DM1 treated samples and also in the in the samples whose trastuzumab treatment were changed to T-DM1 (D) (*, P < 0.05). Note that
CytoDeath positive cells are plotted on different scales.
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These factors which probably differ from tumour to
tumour (or even from cell to cell) might determine
whether the response to T-DM1 is apoptosis or MC.
Further investigations are needed to confirm this
hypothesis.
After inoculation of JIMT-1 cells into SCID mice, we
applied three different treatment strategies with T-DM1.
First, T-DM1 had a partial but significant inhibitory
effect on firmly established subcutaneous tumour
nodules. Second, T-DM1 had an almost complete inhi-
bitory effect on xenograft tumour formation when the
drug administration was started at the time of tumour
cell suspension inoculation. This was carried out to
mimic the adjuvant post-operative therapy situation of
Figure 6 Histological characterization of T-DM1 induced changes in JIMT-1 xenografts. JIMT-1 xenografts were obtained from mice
treated with trastuzumab (A, C, E) or T-DM1 (B, D, F). Histological sections were stained with hematoxylin and eosin (H&E, A, B). HER2 protein
was visualized by HercepTest (C-D). Apoptotic cells were visualized by M30 CytoDeath antibody (E-F). High number of cells with aberrant mitotic
shape (yellow arrow) and giant multinucleated cells (green arrow), which are the hallmarks of mitotic catastrophe, were seen in T-DM1 treated
samples (B, D, F). Furthermore, higher number of apoptotic cells was found in the T-DM1 treated samples than in the trastuzumab treated ones
(white arrow, E and F, respectively). Similar number of cells with normal mitotic shape (blue arrow) was found in trastuzumab and T-DM1
treated samples (A). Tumour cells retained their HER2 positivity after long-term trastuzumab (C) or T-DM1 treatment (D), approximately 9 and 15
wks, respectively. HER2 positive intracytoplasmic granules (red arrow) were seen in T-DM1 treated tumours (D), while not in trastuzumab treated
ones (C). Giant multinucleated cells were strongly positive for cell membrane HER2 protein (green arrow, D).
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chemotherapy naïve patients. Despite a very significant
therapeutic effect, tumours started to grow after 15
weeks in four out of six mice. Residual cancer cells were
found in the fifth mouse microscopically; however, a
complete cure was seen in the sixth mouse. In the third
therapeutic situation, T-DM1 given after trastuzumab
was unable to inhibit tumour growth. These tumours
were larger at the time of T-DM1 administration than
the tumours in the first two treatment strategies. How-
ever, even in these tumours, T-DM-1 caused histologi-
cally detectable mitotic catastrophe and apoptosis.
These observations suggest that efficacy of T-DM1 is
largely dependent on tumour burden of the JIMT-1
xenograft model used.
Our experiments measuring antibody-mediated cellu-
lar cytotoxicity (ADCC) clearly indicated that the cyto-
toxic mechanism of released DM1 is not the only one
for T-DM1. We showed that trastuzumab and T-DM1
evoked similarly effective ADCC on HER2 positive tar-
get cells. Because ADCC has an important role in the
efficacy of trastuzumab in vivo [10,11], this could be one
explanation for better efficacy of T-DM1 in a low
tumour burden in vivo situation.
Finally, we reported immunohistochemical findings of
HER2 expression after prolonged trastuzumab and T-
DM1 treatments. First, we found no obvious changes in
HER2 expression level when T-DM1 treated tumours
were compared to those from trastuzumab treated or
control animals. Second, intense (3+) staining reaction
detected by antibodies against intracellular and extracel-
lular epitopes of HER2 suggests that the majority of
HER2 protein in JIMT-1 xenografts is intact after T-
DM1 and T treatments. Thus, in the JIMT-1 model sys-
tem, appearance of the truncated p95-HER2 protein is
probably minimal and does not explain emerging resis-
tance. Third, in tumours treated with T-DM1 we found
an accumulation of HER2 staining positive intracellular
granules of variable size. Morphologically these granules
resembled enlarged lysosomes. This could be an indica-
tion of a defect in the intracellular trafficking of HER2
protein induced by T-DM1. These issues warrant further
studies both for their biologic and clinical relevance.
Conclusions
We investigated the effect and mechanism of action of a
recently developed antibody-drug conjugate (trastuzu-
mab-DM1, T-DM1). We found that T-DM1 is highly
effective even on breast cancer cell lines cross-resistant
to trastuzumab and lapatinib in vitro. Using a trastuzu-
mab-resistant xenograft tumour model, we showed that
trastuzumab-DM1 can induce both apoptosis and mito-
tic catastrophe in vivo. The latter is a previously unde-
scribed mechanism of action of T-DM1.
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